Title of article :
INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support): A New Paradigm for Translating Registry Data Into Clinical Practice
Author/Authors :
Miller، نويسنده , , Marissa A. and Ulisney، نويسنده , , Karen and Baldwin، نويسنده , , J. Timothy، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2010
Pages :
3
From page :
738
To page :
740
Abstract :
Objectives al of this study was to guide bone marrow-derived human mesenchymal stem cells (hMSCs) into a cardiac progenitor phenotype and assess therapeutic benefit in chronic myocardial infarction. ound stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart disease. Pre-emptive lineage pre-specification may optimize therapeutic outcome. s ere harvested from a coronary artery disease patient cohort. A recombinant cocktail consisting of transforming growth factor-beta1, bone morphogenetic protein-4, activin A, retinoic acid, insulin-like growth factor-1, fibroblast growth factor-2, alpha-thrombin, and interleukin-6 was formulated to engage hMSC into cardiopoiesis. Derived hMSC were injected into the myocardium of a nude infarcted murine model and followed over 1 year for functional and structural end points. s gh the majority of patient-derived hMSC in their native state demonstrated limited effect on ejection fraction, stem cells from rare individuals harbored a spontaneous capacity to improve contractile performance. This reparative cytotype was characterized by high expression of homeobox transcription factor Nkx-2.5, T-box transcription factor TBX5, helix–loop–helix transcription factor MESP1, and myocyte enhancer factor MEF2C, markers of cardiopoiesis. Recombinant cardiogenic cocktail guidance secured the cardiopoietic phenotype across the patient cohort. Compared with unguided counterparts, cardiopoietic hMSC delivered into infarcted myocardium achieved superior functional and structural benefit without adverse side effects. Engraftment into murine hearts was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induction of myocardial cell cycle activity. sions cardiopoiesis thus enhances the therapeutic benefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy.
Keywords :
ventricular assist device , Centers for Medicare and Medicaid Services , and Blood Institute , Food and Drug Administration , lung , Randomized clinical trial , REGISTRY , mechanical circulatory support , Heart Failure , transplant , National Heart
Journal title :
JACC (Journal of the American College of Cardiology)
Serial Year :
2010
Journal title :
JACC (Journal of the American College of Cardiology)
Record number :
1748129
Link To Document :
بازگشت